{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Ss-31",
    "classification": {
      "category": "approved_human",
      "needs_prescription": true,
      "notes": "SS-31 (elamipretide) is a mitochondria-targeting peptide studied clinically for mitochondrial dysfunction-related conditions."
    },
    "status": {
      "category": "approved_human",
      "human_use_note": "Prescription drug in certain jurisdictions; this app provides educational information only."
    },
    "risk": {
      "current_score": 6,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "regulatory_label",
      "rationale": "Human clinical exposure exists; risks depend on indication, dosing, and patient factors.",
      "unknowns_penalty": true,
      "developmental_risk": true,
      "risk_score": 6
    },
    "sections": {
      "overview": [
        {
          "text": "SS-31 (elamipretide) is a mitochondria-targeting peptide that binds cardiolipin and is studied for improving mitochondrial function. This is an educational summary; see evidence links.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "current_outlook_bullets": [
        "sS-31 (elamipretide) is a mitochondria-targeting peptide that binds cardiolipin and is studied for improving mitochondrial function",
        "an educational summary; see evidence links",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "SS-31 (Elamipretide) â€” PubMed search (reference index)",
        "source_type": "website",
        "source_id": "https://pubmed.ncbi.nlm.nih.gov/?term=elamipretide%20SS-31",
        "evidence_grade": "human_interventional"
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_longevity_aging"
      ]
    },
    "slug": "ss-31"
  },
  "canonical_name": "Ss-31",
  "interactions": {
    "drug_classes": [],
    "supplement_classes": null,
    "peptides": null
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "SS-31 is a mitochondria-targeted peptide studied in select clinical research contexts. Consumer wellness narratives often run ahead of evidence; practical risk includes overinterpretation and unregulated sourcing.",
    "benefits": [
      "Interest in mitochondrial function and fatigue-related symptoms (research interest)",
      "Interest in recovery and resilience narratives (community use)",
      "Interest in age-related decline narratives (community use)"
    ],
    "side_effects_common": [
      "Headache",
      "Nausea",
      "Fatigue",
      "Injection-site irritation (if injected)"
    ],
    "side_effects_serious": [
      "Severe allergic reaction (hives, facial swelling, trouble breathing)",
      "Severe dizziness, fainting, or chest pain",
      "High fever or severe systemic symptoms"
    ],
    "who_should_be_cautious": [
      "People with significant cardiovascular disease or unstable medical conditions",
      "Pregnant or breastfeeding individuals",
      "Anyone under 18"
    ]
  }
}
